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Abstract 23 
 24 
          Myelodysplastic syndromes are a group of neoplasms characterized by ineffective 25 
myeloid hematopoiesis and various risks for leukemia. SRSF2, an SR family member of 26 
splicing factors, is one of the mutation targets associated with poor survival in patients of 27 
myelodysplastic syndromes. Here we report the biological function of SRSF2 in hematopoiesis 28 
on conditional knockout mouse models. Ablation of SRSF2 in the hematopoietic lineage 29 
caused embryonic lethality, and Srsf2-deficient fetal liver cells showed significantly enhanced 30 
apoptosis and decreased hematopoietic stem/progenitor cells. Induced ablation of SRSF2 in 31 
adult Mx1Cre/ Srsf2flox/flox mice upon polyinosinic:polycytidylic acid injection demonstrated a 32 
significant decrease in lineage-/Sca+/cKit+ cells in bone marrow. To reveal the functional 33 
impact of myelodysplastic syndromes-associated mutations in SRSF2, we analyzed splicing 34 
responses on a MDS-L cell line and found that the P95H missense mutation and P95 to R102 35 
in-frame 8 amino-acid deletion caused significant changes in alternative splicing. The affected 36 
genes were enriched in cancer development and apoptosis. These findings suggest that intact 37 
SRSF2 is essential for the functional integrity of the hematopoietic system, and its mutations 38 
likely contribute to development of myelodysplastic syndromes.  39 
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Introduction 40 
          Multiple classes of genetic aberrations have been suggested as the cause of 41 
myelodysplastic syndromes (MDS) (1, 2), including mutations in signal transduction, 42 
transcription factors, and epigenetic modifiers (3-5). Interestingly, recent genome-wide 43 
sequencing studies reveal that mutations in genes encoding splicing factors are commonly 44 
associated with MDS and other hematological malignancies (6-15). One of these newly 45 
identified genes encodes for the splicing factor SRSF2 (also known as SC35), and its 46 
mutations have been linked to poor survival among MDS patients (16, 17). Most of the SRSF2 47 
mutations occurred at proline 95, and the majority of these mutations changed this proline to 48 
histidine (P95H); less frequent changes to leucine (P95L), arginine (P95R), and in-frame 49 
deletion of 8 amino acids from P95 to R102 (Δ8aa) have also been reported (6, 16, 18-20). 50 
However, the causal effect of these mutations on MDS development has remained to be 51 
established. 52 
          SRSF2 is one of the founding members for the SR protein family of splicing factors (21). 53 
It is involved in both constitutive and regulated splicing. Homozygous germline knockout (KO) 54 
mice of Srsf2 are embryonic lethal (22), and conditional knockout (cKO) mice display various 55 
tissue-specific phenotypes (22-24). Importantly, Srsf2 down-regulation in mouse embryonic 56 
fibroblasts results in G2/M cell cycle arrest and genomic instability (23). To date, systematic 57 
analysis of SRSF2 function in the blood system has not been reported except for its 58 
requirement in T-cell development (24). Given the tight link of Srsf2 mutations to MDS, we aim 59 
to directly test the hypothesis that SRSF2 plays an important role in normal hematopoiesis, 60 
and that SRSF2 mutations induce specific changes in alternative splicing that favor disease 61 
progression.  62 
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          Here we analyzed SRSF2 function in hematopoiesis on two mouse models by crossing 63 
cKO mice with blood cell-specific Vav-iCre mice and interferon-inducible Mx1Cre mice. We 64 
also generated an inducible shRNA/cDNA expression system to replace endogenous SRSF2 65 
with specific mutants in a MDS cell line to evaluate the splicing response to mutant SRSF2 by 66 
RNA-mediated oligonucleotide annealing, selection, and ligation coupled with next-generation 67 
sequencing (RASL-seq) (25, 26). We report that SRSF2 is essential for the survival of 68 
hematopoietic cells in developing embryos and adults, and that its mutant forms switch the 69 
RNA splicing profile on a large panel of genes involved in cancer development and apoptosis. 70 
Together, these data suggest that SRSF2 mutations identified in MDS are not simply loss-of-71 
function mutations but instead alter SRSF2 function in RNA splicing. Such changes may 72 
directly contribute to MDS development and later progression to more aggressive forms of 73 
leukemia.  74 
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Materials and Methods 75 
Mice 76 
C57BL/6 (CD45.2), congenic strain B6.SJL-Ptprca Pep3b/BoyJ (PEP3, CD45.1) mice, 77 
Vav-iCre and Mx1Cre mice were obtained from Jackson Laboratory. Conditional Srsf2f/f mice of 78 
C57BL/6 background were described previously (24). For embryo analyses, Srsf2f/f mice were 79 
mated with Vav-iCre +Srsf2f/+ mice. To collect peripheral blood, embryos were bled from 80 
umbilical cord into PBS. Fetal livers from embryonic day 14.5 (E14.5) were fixed in 4% 81 
formaldehyde/PBS, and the tissue section was stained with Hematoxylin-Eosin. 82 
Polyinosinic:polycytidylic acid (Poly IC, Sigma) was injected intraperitoneally (i.p.) either 250 μ83 
g/body every other day for a total of 3 injections or 600 μg/body as indicated. Age-matched 84 
adult mice (8 -12 weeks old) were used for experiments. The day of the first injection was 85 
defined as day 0. Both protocols resulted in similar knock-down efficiency. Genotyping PCR 86 
was performed using primers described previously (23). All the procedures were approved by 87 
the institutional animal care and use committee.  88 
 89 
DNA Constructs 90 
          C-terminally HA-tagged human SRSF2 was subcloned in the EcoRI site of MSCV-IRES-91 
GFP (MigR1) , MSCV-IRES-puro (MIP), and pREV-TRE (23). P95H and Δ8aa mutants were 92 
made by PCR mutagenesis. Primers used for mutagenesis are as follows. P95H(F): CAAATG 93 
GCGCGCTACGGCCGCCACCCGGACTCACACCACAGCCGC. P95H(R): 94 
GCGGCTGTGGTGTGAGTCCGGGTGGCGGCCGTAGCGCGCCATTTG. Δ8aa(F): 95 
CGGGTGCAAATGGCGCGCTACGGCCGCCGGGGACCGCCACCCCGC AGGTACGGGG. 96 
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Δ8aa(R): CCCCGTACCTGCGGGGTGGCGGTCCCCGGCGGCCGTAGCGCGCCA 97 
TTTGCACCCG. pTRIPZ-SRSF2 constructs were made using shRNA against the 3’-UTR of 98 
human WT SRSF2 (CTCTCCCGATTGCTCCTGTGTA) and human SRSF2 cDNA sequences 99 
with or without mutations. 100 
 101 
Cell culture 102 
         293T cells, mouse fetal liver (FL) cells (E12.5-E14.5), total BM cells and lineage-depleted 103 
BM cells (sorted by using Lineage depletion kit from Miltenyi) were cultured as described 104 
before (27). To make single cell suspension of FL cells, FLs were sheared in PBS by pipetting, 105 
passed through 40 µm cell strainers, and treated with ACK buffer [150 mM NH4Cl, 1 mM 106 
KHCO3, 0.1 mM EDTA] when necessary. MDS-L cells (28, 29) were kindly provided by Dr. 107 
Daniel Starczynowski (Cincinnati Children's Hospital Medical Center), and cultured in RPMI 108 
supplemented with 10% fetal bovine serum, penicillin/streptomycin and 10 ng/ml human IL-3 109 
(hIL-3) (Peprotech). To induce the expression of shRNA and exogenous SRSF2 in MDS-L cell 110 
lines transduced with pTRIPZ vectors, 1 μg/ml Doxycycline (Sigma) was added every day to 111 
the cells for three days. To reach 50% SRSF2 expression in shRNA only cells, 2.5 μg/ml 112 
Doxycycline was used in the assay. Cell growth was evaluated in duplicate by the Trypan blue 113 
exclusion assay. As for colony forming unit (CFU) assays, specific numbers of cells (described 114 
in figure legends) were seeded into M3434 (STEMCELL Technologies). One week later, 115 
colony number was counted.  116 
 117 
Flow cytometry 118 
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 Primary cells from mice (FL, PB and BM cells) were treated with ACK buffer at room 119 
temperature for 5 minutes. For PB staining, B cell lineage (APC-conjugated B220), T cell 120 
lineage (PerCP-Cy5.5-conjugated CD4 and CD8a), or granuolocyte lineages (PE-conjugsted 121 
Gr1 and CD11b) were used. For FL staining, lineage cocktail was CD3, CD4, CD8a, Gr1, B220, 122 
CD19 and Ter119. For adult BM lineage cocktail, CD11b was added to that of FL. All of these 123 
antibodies are conjugated to PerCP-Cy5.5. Sca-1-APC, c-Kit-PECy7, CD48-PE and CD150-124 
Biotin (all these antibodies from eBioscience) together with streptavidin-APC-Alexa Fluor 750 125 
(Invitrogen) were used for SLAM staining. Data were collected on FACSCanto or FACSCalibur 126 
(both from BD), and analyzed by FACSDiva (BD) or FlowJo software (Treestar). For the 127 
apoptosis assay, Annexin V-APC apoptosis kit (BD) was used. Cell cycle was evaluated by 128 
Pyronin Y and 7AAD staining (30).  129 
 130 
Reverse transcription (RT) and quantitative polymerase chain reaction (qPCR)  131 
           Total RNA was extracted by using Trizol (Life Technologies) and treated with DNase I 132 
(Qiagen). RT reactions were carried out by using the qScript cDNA Synthesis Kit (Quanta 133 
Biosciences). qPCR was performed with the SYBR FAST qPCR Kit (KAPA Biosystems). For 134 
validation of the results of RASL-seq, OneStep RT-PCR kit (Qiagen) was used. Primers used 135 
for RT-PCR and qPCR are as follows. mSrsf2(F): CGCGCTCCAGATCAACCTC. mSrsf2(R): 136 
CTTGGACTCTCGCTTCGACAC. mGAPDH(F): GGTGCTGAGTATGTCGTGGAGTCTA. mGAPDH(R): 137 
AAAGTTGTCATGGATGACCTTGG. hSRSF2 3’-UTR(F): GCACTAGGCGCAGTTGTGTA. hSRSF2 3’-138 
UTR(R): CAATCGGGAGAAAACAGGAA. hSRSF2 Exon2 CDS(F): CTACAGCCGCTCGAAGTCTC. 139 
hSRSF2 Exon2 CDS(R): TTGGATTCCCTCTTGGACAC. hGAPDH(F): TCGCTCAGACACCATGGGGAAG. 140 
hGAPDH(R): GCCTTGACGGTGCCATGGAATTTG. 141 
 142 
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Western blotting 143 
Cell extracts from mouse bone marrow were prepared with Thermo Scientific Pierce IP 144 
Lysis Buffer (PI-87787) including the protease inhibitor cocktail (PI-88665) and phosphatase 145 
inhibitor cocktail (PI-88667). Western blotting was performed following standard procedures. 146 
Protein samples were denatured in 1× loading buffer [10% glycerol, 2% SDS, 10 mM DTT and 147 
50 mM Tris-HCl (pH 6.8)]. Protein concentration was adjusted and protein samples were 148 
loaded on SDS polyacrylamide gels after adding bromophenol blue (0.05%). Primary anti-149 
SRSF2 antibody (ab28428; Abcam) and anti-β-actin antibody (A1978; Sigma-Aldrich) were 150 
used. Signals from fluorophore-conjugated secondary antibodies were detected with the 151 
Odyssey system (LI-COR). 152 
 153 
Retrovirus infection 154 
          Virus infection procedure was performed as described previously (27). For general 155 
retrovirus infection, 293T cells were transfected with 5 µg of retrovirus vectors and with 5 µg of 156 
Ecopac packaging vector using polyethylenimine (Polysciences Inc). The 293T medium was 157 
changed from DMEM to IMDM 10 hrs post transfection. Retroviral supernatants were 158 
harvested 48 hrs after transfection and filtered through a 0.45 μm filter. The supernatant was 159 
added to primary bone marrow cells, along with 4% IL3-CM, 4%SCF-CM, 1% HEPES and 0.1% 160 
polybrene (final concentration 4 μg/mL). The cells were spinoculated at 1200 × g for 3 hrs at 32° 161 
C. Infections were performed twice on consecutive days. For overexpression of WT and 162 
mutant SRSF2, BM cells were transduced with MIP vector or MIP-SRSF2 expression 163 
retrovirus by two rounds of infection, selected in 1 µg/mL puromycin for 3 days before assays. 164 
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          For lentivirus production, 293T cells were transfected with pTRIPZ lentivirus vectors, 165 
pCMV-VSVG, and pCMV-dR8.2 using lipofectamine 2000 (Life Technologies) for 6 hrs and 166 
then the medium was changed. Forty-eight hours later, culture supernatant was harvested, 167 
and filtered through a 0.45 μm filter. For viral transduction, RPMI1640 medium with 10 ng/ml 168 
hIL-3 was diluted with viral supernatant at 1:1 ratio. The MDS-L cells were then cultured in the 169 
mixed medium with 8 μg/ml polybrene overnight. Next day, medium was changed, and the 170 
stable cell lines with incorporated viral DNA segments were selected in 2 μg/ml puromycin for 171 
7 days. 172 
 173 
Stress hematopoiesis 174 
          5-FU (GeneraMedix) was injected i.p. every week (150 mg/kg body weight). Survival 175 
was monitored every day. The combined results of independent two experiments are shown. 176 
          For sublethal irradiation, mice received 4 Gy total body irradiation. Cell counts were 177 
followed up. 178 
 179 
Bone marrow transplantation assay 180 
For bone marrow transplantation (BMT) of Srsf2-overexpressed cells, donor C57BL/6 181 
mice were injected i.p. with 150 mg/kg body weight 5-Fluorouracil (5-FU) five days prior to 182 
bone marrow harvest. BM cells were harvested, treated with ACK buffer, and washed with 183 
PBS. Cells were transduced with MigR1, MigR1-SRSF2WT, and MigR1-SRSF2P95H vectors. 184 
GFP percentage was adjusted to 17% using uninfected cells. Infected BM cells were injected 185 
into lethally irradiated recipient mice (9 Gy) through the tail veins. Recipient mice were given 186 
acidic water (pH 4.0) for three weeks following BMT. 187 
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          For competitive and non-competitive BMT, total BM cells were harvested from indicated 188 
donor mice without treatment. In non-competitive settings, 2 million test cells in 200 µL PBS 189 
were injected into lethally irradiated (9 Gy) recipient PEP3 mice. In competitive settings, test 190 
cells were mixed with competitor cells (PEP3 cells) 1:1, and 2 million cells were injected into 191 
lethally irradiated recipient PEP3 mice.  192 
 193 
RASL-seq 194 
          Doxycycline (Dox, Sigma) at indicated concentration was added to MDS-L cell culture 195 
every day for 3 days. Total RNA was extracted from cells, and used for RASL-seq. Analysis of 196 
splicing changes was described previously (25, 26). Gene function and pathway analyses were 197 
performed using QIAGEN’s Ingenuity® Pathway Analysis (IPA®, QIAGEN Redwood City, 198 
www.qiagen.com/ingenuity). Original data is uploaded to GSE (GEO accession 199 
number: GSE61052). 200 
 201 
Statistics 202 
All the experiments were repeated at least twice. Results were represented as mean ± 203 
standard deviation (SD) unless otherwise stated. Comparison between two groups was done 204 
by t-test. Survival data were presented as Kaplan-Meyer curves, and Log-rank test was 205 
performed. p < 0.05 was considered as significant and shown by asterisk.  206 
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Results 207 
 208 
Srsf2 is essential for viability of blood cells in vitro 209 
          To test the functional requirement of Srsf2 in blood cells, we first pursued an in vitro 210 
model by infecting bone marrow (BM) cells derived from adult Srsf2+/+ and Srsf2f/f mice with 211 
MSCV-Cre-IRES-EYFP (Cre) or empty vector (MSCV-IRES-EYFP) (EV) retrovirus. In the 212 
absence of Cre expression, Srsf2+/+ (+/+ EV) and Srsf2f/f (f/f EV) cells did not show any growth 213 
difference. However, in the presence of Cre expression, Srsf2f/f cells (f/f Cre) exhibited a clear 214 
growth disadvantage compared to Srsf2+/+ cells (+/+ Cre) (Figure 1A). In addition, Cre-infected 215 
Srsf2f/f (f/f Cre) cells were significantly more apoptotic compared to other groups (Figure 1B). 216 
These results demonstrate that Srsf2 is essential for blood cell growth and survival in vitro. 217 
 218 
Srsf2 plays an indispensable role in the development of the hematopoietic system in 219 
mice 220 
          To pursue the functional impact of Srsf2 deletion on hematopoietic cells under in vivo 221 
conditions, we first crossed Srsf2f/f mice with blood cell-specific Cre transgenic mice (Vav-iCre) 222 
(31). Fetal liver (FL) hematopoiesis was analyzed in multiple sets of littermates at embryonic 223 
day 12.5 and 14.5 (E12.5 and E14.5). Compared to others, Vav-iCre+Srsff/f (Srsf2Δ/Δ) embryos 224 
had paler and smaller FL (Figure 2A), which contained significantly fewer definitive blood cells 225 
(10% of wild type controls at E14.5) (Figure 2B). The remaining cells in Srsf2Δ/Δ FL exhibited 226 
more apoptosis and quiescence (Figure 2C-D), which is compatible with the in vitro data 227 
(Figure 1B). Histological study on E14.5 FLs showed that erythroblasts and mature 228 
granulocytes were not detectable in Srsf2Δ/Δ FLs (Figure 2E). Srsf2Δ/Δ embryos died during 229 
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embryonic development between E16.5-E18.5 with severe anemia and edema (Table 1 and 230 
data not shown). These results demonstrate the essential role of Srsf2 in hematopoiesis during 231 
embryonic development. 232 
          To further characterize the defects in FL hematopoiesis, we next examined 233 
hematopoietic stem/progenitor cells (HSPCs) in FLs by flow cytometry. Importantly, we 234 
detected no HSPCs (lineage-/cKit+) in E14.5 Srsf2Δ/Δ FL hematopoietic cells (Figure 3A-B). In 235 
agreement with this result, a colony forming assay of E12.5 FL cells showed that Srsf2Δ/Δ cells 236 
had significantly lower clonogenicity (Figure 3C). Differential counts of colonies did not show 237 
significant changes between any groups (data not shown). In addition, peripheral blood (PB) of 238 
Vav-iCre+Srsf2f/f (Srsf2Δ/Δ) embryos had significantly higher primitive red blood cells as shown 239 
by the number of nucleated erythrocytes (Figure 3D-E). Throughout these experiments, Δ/+ 240 
embryos did not show significant difference compared to +/+, suggesting that one allele is 241 
sufficient for normal HSC function. Thus, Srsf2 is essential for the survival of embryonic 242 
HSPCs. 243 
 244 
Srsf2 is required for survival of adult BM cells 245 
          Haploinsufficient expression of certain critical hematopoietic regulators, such as RUNX1 246 
and PU.1, has been shown to affect both the number and distribution of different populations of 247 
blood cells (32, 33).   Interestingly, most reported mutations of SRSF2 in MDS are monoallelic, 248 
suggesting potential haploinsufficiency of SRSF2 in disrupting hematopoiesis. To explore this 249 
possibility, we tested whether adult heterozygous mice (Vav-iCre+Srsf2f/+, Δ/+) had recordable 250 
phenotypes relative to control mice (Vav-iCre-Srsf2f/+, f/+). Srsf2 expression, measured by RT-251 
qPCR and western blot, was almost half in Δ/+ BM cells compared to their f/+ counterpart (data 252 
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not shown). We detected little difference between WT and heterozygous mice based on blood 253 
counts under either normal or stressed conditions [cell count recovery after sublethal 254 
irradiation (4 Gy) or weekly 5-FU injection (150 mg/kg), aging stress up to 10 months] (data not 255 
shown). These results suggest that SRSF2 level remains half in the heterozygous mice and its 256 
expression from one allele is sufficient for maintaining its normal cellular function. 257 
          Lack of SRSF2 in the developing heart resulted in dilated cardiomyopathy, while cKO of 258 
mature cardiomyocytes did not have any obvious phenotype (22, 23). These reports suggest 259 
that loss of SRSF2 can result in different phenotypes at different developmental stages. 260 
Therefore, we also evaluated the effect of SRSF2 ablation in adult blood cells. We crossed 261 
Srsf2f/f mice with Mx1Cre mice to generate polyinosinic:polycytidylic acid (polyIC)-inducible 262 
Srsf2 knockout mice. Interestingly, Mx1Cre+Srsf2f/f mice stayed alive at least for 3 months after 263 
seven injections of 600 µg/dose polyIC (data not shown). Genotyping of blood and BM cells 264 
showed incomplete excision of the floxed Srsf2 allele in blood and BM cells from 265 
Mx1Cre+Srsf2f/f mice. In contrast, we detected nearly complete ablation of the floxed allele in 266 
blood and BM cells from heterozygous Mx1Cre+Srsf2f/+mice (Figure 4A). Genotyping of 267 
colonies derived from single bone marrow cells confirmed incomplete knockout showing both 268 
floxed and deleted bands in Mx1Cre+Srsf2f/f cells (data not shown). These results indicate a 269 
high level of selection pressure against the loss of Srsf2. On day 16, polyIC-treated 270 
Mx1Cre+Srsf2f/f mice had significantly decreased platelet counts in their PB (Figure 4B). Other 271 
examined blood parameters, including neutrophil counts, percentage of myeloid 272 
(Gr1+/CD11b+), B (B220+), and T (CD4+/CD8+) cells were normal (data not shown). 273 
Decreased counts of white blood cells and lymphocytes in Mx1Cre+Srsf2f/+ and 274 
Mx1Cre+Srsf2f/f mice were observed (data not shown), which is possibly due to Cre expression. 275 
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Importantly, BM showed a significant decrease in total BM cell counts, absolute number of 276 
Lineage-/Sca-1+/c-Kit+ (LSK) cells in total BM, and percent of LSK cells in BM of 277 
Mx1Cre+Srsf2f/f mice compared to Mx1Cre-Srsf2f/f controls (Figures 4C-E). SLAM staining 278 
using CD150 and CD48 antibodies did not record any significant change in the ratios of 279 
positive and negative cells (data not shown). These results suggest that the immature BM 280 
fraction (LSK) was more susceptible to the loss of SRSF2 compared to further differentiated 281 
cell populations.  282 
          To further establish that the observed phenotypes are cell-autonomous, we performed 283 
competitive bone marrow transplantation (BMT) of Mx1Cre+Srsf2f/f BM cells (Figure 4F). One 284 
month after BMT, Mx1Cre+Srsf2f/f recipients showed significantly lower engraftment even 285 
before polyIC injection, possibly due to high interferon sensitivity of Mx1Cre+Srsf2f/f cells 286 
induced early in the BMT procedure (34). PolyIC injection caused further decrease of donor 287 
chimerism in these mice. These results thus demonstrate the cell autonomous effect of Srsf2 288 
ablation on the survival of immature hematopoietic stem cells. 289 
 290 
Srsf2 overexpression also causes a growth disadvantage 291 
          Single allele SRSF2 mutations have been commonly identified in MDS patient (6, 16, 17, 292 
19). On the other hand, heterozygous deletion of Srsf2 in blood cells of Vav-iCre+Srsf2f/+ 293 
(Figures 2-3) and polyIC -treated Mx1Cre+Srsf2f/+ mice (Figures 4) did not show obvious 294 
phenotypes. These results suggest that SRSF2 mutations in MDS are not simply loss-of-295 
function mutations but rather reflect altered functions. We wished to further test the hypothesis 296 
of altered function under overexpression conditions, by selecting the MDS-associated P95H 297 
missense mutation and in-frame 8 amino-acid deletion (Δ8aa, P95 to R102 deletion) to 298 
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compare with WT SRSF2. MIP vector and MIP-WT, -P95H, and -Δ8aa SRSF2 retroviruses 299 
were used to infect murine bone marrow cells. The exogenously expressed WT, P95H, and Δ300 
8aa SRSF2 protein is 4-7 fold above the endogenous SRSF2 level (Figure 5A). Liquid culture 301 
of infected cells showed growth suppression by both WT and mutant SRSF2 under such 302 
overexpression conditions (Figure 5B). Importantly, the cells expressing the mutant SRSF2 303 
showed a significant increase in apoptosis relative to their WT counterpart (Figure 5C), though 304 
cell cycle was not inhibited (data not shown). Consistent with the liquid culture data, the colony 305 
forming assay showed significantly lower colony and cell numbers in WT-infected cells, which 306 
were even lower in P95H and Δ8aa cells compared to the MIP infected cells (Figure 5D). The 307 
colony types (GEMM, BFU-E, CFU-G, CFU-GM and CFU-GM), surface markers (Gr-1 and 308 
CD11b), and cell morphology were not different among the groups (data not shown). These 309 
results suggest that increased expression of SRSF2 mainly affects cell survival but does not 310 
disrupt myeloid cell differentiation. More importantly, overexpression of the P95H and Δ8aa 311 
mutants always showed stronger negative effects on cell survival than the WT SRSF2. 312 
          We next performed a transplantation of SRSF2 overexpressing bone marrow cells to 313 
evaluate the repopulation ability in vivo. The percentage of GFP+ cells in PB of WT- and 314 
P95H-cell recipients was lower than in MigR1-cell recipient mice. However, the difference 315 
between the WT and P95H groups was not significant (Figure 5E). Lineage staining of GFP+ 316 
PB cells did not show lineage skewing (myeloid vs lymphoid) in response to overexpression of 317 
WT or mutant SRSF2 (data not shown). Furthermore, these cells did not show a difference in 318 
dysplastic morphology in PB and BM during the observation of 10 months (data not shown). 319 
Data in these experiments suggest that overexpressed WT and P95H both caused significant 320 
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growth disadvantage, which was also accompanied by induced apoptosis. However, neither 321 
appears to have any recordable effect on cell differentiation both in vitro and in vivo. 322 
 323 
SRSF2 Mutants altered a large RNA splicing program 324 
         Although our functional analysis of overexpressed SRSF2 is consistent with earlier 325 
reports of overexpressed SR proteins interfering with developmental processes (35-37), the 326 
data indicate a clear advantage in studying the mutant function of SRSF2 in cellular systems 327 
that may enable us to recapitulate SRSF2 single allele mutations in MDS patients. We 328 
generated a relatively low-level expression system by lowering endogenous SRSF2 with 329 
shRNA and simultaneously expressing the mutant version of the protein in a human MDS cell 330 
line (MDS-L) (28, 29). This cell line was derived from an MDS patient and has a chromosome 331 
5q deletion but no mutation in splicing factors SRSF2 or U2AF1 (confirmed by re-sequencing, 332 
data not shown). We constructed Tet-inducible lentivirus vectors to co-express an shRNA 333 
targeting the 3’-UTR of endogenous SRSF2 and an shRNA-resistant form of SRSF2 cDNA 334 
(WT or mutants) (Figure 6A). MDS-L cells were transduced with SRSF2 shRNA/cDNA 335 
lentivirus to establish pools of shRNA/WT, P95H, and Δ8aa inducible expressing cells. 336 
Doxycycline (Dox) treatment reduced endogenous SRSF2 (shown by 3’-UTR expression) 337 
while inducing relatively low overexpression of total SRSF2 RNA (3 to 4 fold of the 338 
endogenous level) [shown by exon 2 coding sequence (CDS)] (Figure 6B). Under these 339 
conditions, mutant cells (P95H and Δ8aa) showed significant growth arrest and enhanced 340 
apoptosis compared to WT cells (Figure 6C-D). However, cell cycle analysis did not show any 341 
obvious change except for a detectable increase in sub-G0/G1 cells (data not shown). These 342 
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data indicate that the system closely mimics certain MDS conditions in a disease-relevant cell 343 
line. 344 
Although it is widely anticipated that SRSF2 mutations will perturb the splicing program 345 
in diseased cells, the global impact of SRSF2 mutations on regulated splicing has not been 346 
investigated. To reveal potential functional differences between WT and mutant SRSF2 that 347 
may be relevant to MDS development, we examined the splicing response by using the RASL-348 
seq platform, which was designed to detect annotated 5530  alternatively spliced mRNA 349 
isoforms in the human genome (26). MDS-L cells co-expressing Tet-inducible SRSF2 shRNA 350 
and WT, P95H, or Δ8aa SRSF2 were cultured with or without Dox for 3 days to modulate 351 
SRSF2 expression. Total RNA was isolated from these cells for splicing profiling.  352 
Based on a stringent cutoff (a fold ratio change >1.5 and p-value<0.05), we detected 353 
both overlapped and separated changes in splicing upon expression of WT and mutant SRSF2 354 
(Figure 7A-B, Table S1-5), indicating that MDS-associated mutations have a shared function 355 
with and an independent effect from WT SRSF2 on splicing. Relative to WT cells, P95H and 356 
∆8aa mutants induced a common set of 487 events, 470 of which were altered in the same 357 
directions, including 164 enhanced cassette exon inclusion and 306 enhanced cassette exon 358 
exclusion (Figure 7C, Table S6). Importantly, P95H and ∆8aa mutants each induced 210 and 359 
483 extra events, respectively. Ten commonly changed splicing events in genes related to 360 
hematopoiesis was selected and validated by RT-PCR (Figure 7D). Similar to shSRSF2 only, 361 
MEIS1, UPF38 and PRKAA1 had increased ratios of short to long isoforms in SRSF2 mutant 362 
cells, suggesting reduction of SRSF2 function of SRSF2 mutants in these splicing events. 363 
RBM23, PDK1, PDE4DIP, MLL and RNF34 had increased while CBFB and SMG7 had 364 
decreased short to long isoform ratios in SRSF2 mutant cells independent of shSRSF2, 365 
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suggesting the gain of function effect of SRSF2 P95H and Δ8aa mutants in these splicing 366 
events. Furthermore, the change of the scale of exon inclusion or exclusion induced by Δ8aa 367 
mutant is over 1.5 times more in 450 out of 470 common events relative to the P95H mutant. 368 
Together, these data suggest that even though the two mutants showed certain overlapping 369 
effects on splicing, they were not functionally equivalent; the deletion mutant may have a more 370 
profound impact on regulated splicing than the P95H mutation. 371 
 To gain functional insights into such a dramatically altered splicing program, we 372 
reasoned that the altered splice events commonly affected by P95H and Δ8aa might be more 373 
related to MDS, while extra events induced by each mutant might be responsible for enhancing 374 
the disease phenotype. We thus focused on the commonly affected set of 470 genes by 375 
applying Ingenuity pathway analysis. Consistent with the functional consequences triggered by 376 
the mutations in our cellular and animal models, we observed cancer development and 377 
apoptosis pathways among the top 10-ranked canonical pathways (Figure 8A). These findings 378 
support the possibility that the MDS-associated mutations in SRSF2 promote the development 379 
of the disease phenotype with potential to induce a cascade of events that lead to both disease 380 
progression and more aggressive types of blood disorders. 381 
To analyze the possible loss or gain of function of the P95H and Δ8aa mutations, we 382 
also examined their 470 commonly affected splicing events in MDS-L cells that expressed only 383 
shRNA of SRSF2 but not any shRNA resistant SRSF2. Upon Dox treatment, SRSF2 384 
expression in these cells was knocked down nearly 50% (data not shown). One hundred thirty-385 
five events (29% of 470) were affected by the SRSF2 reduction (Figure 8B, Table S7). 386 
Interestingly, we detected similar numbers of splicing events changed in the same and the 387 
opposite directions between the SRSF2 mutants and knockdown cells. The remaining 335 of 388 
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470 events were not affected by SRSF2 knockdown. These results suggest that P95H and 389 
Δ8aa mutations lead to loss of function in some splicing events (shared and in the same 390 
direction), enhanced function in some other WT SRSF2 involved splicing events (shared but in 391 
the opposite direction), and also potentially gain of function in regulating new splicing events 392 
(not overlapped). It is possible that some of these combinatory loss and gain effects promote 393 
MDS development. 394 
  395 
KOMENO et al.                     SRSF2 IN HEMATOPOIESIS AND MDS       
20                                 
Discussion 396 
 397 
In this report, we examined the role of SRSF2 in hematopoiesis using the Srsf2 cKO 398 
mouse model. We also analyzed the cellular effect of expressing MDS-related mutant forms of 399 
SRSF2. Our analyses demonstrate that SRSF2 is essential for the survival of blood cells 400 
including HSCs. In the absence of SRSF2, blood cells had increased senescence and 401 
apoptosis. However, unlike previous reports in several other cellular systems, we did not 402 
detect any significant delay of cell cycle in SRSF2-deficient blood cells, nor observed the effect 403 
on differentiation of myeloid cells. Interestingly, ablation of SRSF2 in pituitary cells and 404 
thymocytes results in decreased organ size but no increase of apoptosis (23, 24). Developing 405 
thymocytes showed a differentiation block from CD4/CD8 double negative to double positive 406 
stage (24). Ablation of SRSF2 in the embryonic heart showed normal development but later 407 
suffered from dilated cardiomyopathy (22). However, mice with Srsf2 knockout in post-mitotic 408 
cardiomyocytes stayed normal (23). These different phenotypes of SRSF2 in different cell 409 
types may result from alteration of cell type-specific targets of SRSF2. For example, in 410 
thymocytes lacking SRSF2, the defective splicing of lymphoid cell-specific CD45 RNA has 411 
been related to their abnormal differentiation (23). 412 
 SR proteins including SRSF2 are known to autoregulate their own expression via an 413 
intron retention event in its 3’-UTR (38-40). In response to SRSF2 overexpression, splicing of 414 
this retained intron likely produces an exon junction complex (EJC), triggering nonsense-415 
mediated mRNA decay. As the intron is mostly retained in normal cells, reduction of SRSF2 416 
may have little effect on mRNA stability. Consistently, we detected nearly a 50% decrease of 417 
SRSF2 in Srsf2Δ/+ heterozygous blood cells. In light of a recent report that heterozygous Sf3b1 418 
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deficient mice showed haploinsufficiency in HSCs (41) and because SRSF2 mutations in MDS 419 
patients are generally heterozygous, we examined hematopoiesis in mice with Srsf2 420 
heterozygous blood cells during development and under stress conditions. No obvious 421 
phenotypes were observed, suggesting that the MDS-related heterozygous SRSF2 mutations 422 
are not simply loss-of-function mutations and that MDS may not result from SRSF2 423 
haploinsufficiency. Instead, our data suggest likely gain-of-function mutations in SRSF2, 424 
including potential dominant negative effects that reduce total SRSF2 activity. 425 
It is striking that SRSF2 mutations in MDS mainly occur at proline 95 (P95), suggesting 426 
a critical role of P95 in SRSF2. SRSF2 has an N-terminal RNA recognition (RRM) domain and 427 
a C-terminal arginine and serine rich (RS) domain. The RRM domain is primarily involved in 428 
specific RNA recognition. The RS domain can be highly phosphorylated and is involved in both 429 
RNA binding and protein-protein interactions during spliceosome assembly (21). P95 is 430 
generally believed to be located in the hinge region between the RRM domain and the RS 431 
domain. A recent structural analysis of the N-terminal 101 amino acids of SRSF2 bound to 6-432 
oligonucleotide RNA targets showed that P95 directly contacts the C3 and G3 nucleotides in 433 
RNA containing the UCCAGU and UGGAGU motifs, which represent two consensus SRSF2 434 
binding sequences (42). It is possible that SRSF2 with mutations at P95 decrease the RNA 435 
binding specificity. This possibility is supported by a recent report that unlike the WT SRSF2, 436 
the P95H mutant preferentially binds to CCAG motif (43).  Furthermore, the unique features of 437 
proline among the 20 protein-forming amino acids, including its cis-trans isomerization (44), 438 
CH/Pi hydrogen bond formation (45), and higher conformational rigidity in the secondary 439 
structure of proteins (44), may result in a different local structure to create a new surface for 440 
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interaction with additional proteins and RNA sequences. These are subject to future 441 
biochemical studies. 442 
We compared WT and mutant (P95H, and Δ8aa) SRSF2 by overexpressing them via 443 
MSCV retrovirus transduction. With this approach, exogenously expressed SRSF2 protein is 4 444 
to 7 fold above its endogenous level. Similar inhibitory effects of WT and both mutants on cell 445 
growth, colony formation, and in vivo blood cell repopulation were detected in these 446 
overexpression assays (Figure 5). These results support the above hypothesis that WT and 447 
P95 mutant SRSF2 have certain similar functions, and such functions above normal levels 448 
disrupt hematopoiesis. Interestingly, the negative effects of over expressing the WT SRSF2 449 
and P95H are nearly identical on in vivo repopulation (Figure 5D), suggesting that HSPCs are 450 
likely more sensitive to the level of SRSF2. 451 
We also used the Tet-On system to induce co-expression of an SRSF2 shRNA and an 452 
shRNA-resistant WT or mutant SRSF2 to mimic patient expression levels in the MDS-L cell 453 
line. Under this experimental setting, we detected unique cell growth inhibitory effects of 454 
mutant SRSF2, which is more likely due to the unique gain/loss functions of mutant SRSF2. 455 
Using the RASL-seq platform, we observed that apoptosis and cancer-related pathways 456 
were among the top 10 ranked canonical pathways affected by SRSF2 mutations, which is 457 
consistent with pathology of MDS patient cells (1, 2). MDS cells were noted to be highly 458 
apoptotic at early stages, likely reflecting a key mechanism to eliminate cells and eventually 459 
become malignant (1, 2, 46). Thus, mutant forms of SRSF2 in MDS seem to trigger genomic 460 
instability, and promote accumulation of unwanted oncogenic mutations (47). RASL-seq (25, 461 
26) is a convenient way to screen the alternative splicing changes with multiple advantages, 462 
including (1) the ability to use limited amounts of total RNA for the analysis (typically from 0.1 463 
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to 1 µg of total RNA), (2) considerable tolerance of RNA quality to obtain robust data, (3) the 464 
sensitivity to obtain quantitative information on alternative splicing events in less abundant 465 
transcripts, and (4) the ability for highly parallel analyses of biological samples in a cost-466 
effective manner. However, compared to RNA-seq, RASL-seq is limited to analysis of 467 
annotated alternative splicing events and cannot detect other aberrant RNA processing events. 468 
Despite these limitations, we successfully applied this technique to identify a large cohort of 469 
alternative splicing events uniquely caused by mutant SRSF2, suggesting that the mutant 470 
splicing factor has the capacity to dramatically alter the splicing program in diseased cells. It is 471 
unclear whether the mutant Srsf2 also affects certain constitutive splicing events. 472 
 In conclusion, we demonstrate that SRSF2 is essential for the survival of hematopoietic 473 
cells and that its loss results in apoptosis and growth suppression. No obvious phenotypes 474 
were detected in Srsf2 heterozygous blood cells, but growth arrest and increased apoptosis 475 
were clearly detected in cells expressing either P95H or Δ8aa mutants. Together, these results 476 
support that MDS-related SRSF2 mutations are not simply loss-of-function mutations. 477 
Furthermore, RASL-seq analysis demonstrates that MDS mutant forms of SRSF2 dysregulate 478 
RNA splicing. Future work will be focused on understanding the molecular mechanism of 479 
SRSF2 mutations in MDS development, including their effects on RNA splicing and other 480 
aspects of regulated gene transcription (48, 49). Future studies will also examine how 481 
mutations in SRSF2 may act in synergy with mutations in other key leukemia genes, such as 482 
TET2, IDH2, and RUNX1, to propel MDS progression to more aggressive blood cell disorders.483 
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Table 1. Number of surviving and dead mice with different genotypes of Srsf2.  680 
Day   Genotype 
    f/+ f/f Δ/+ Δ/Δ 
E11.5   4 2 1 3 
E12.5 
 
5 2 1 0 
E13.5 
 
3 3 1 0 
E14.5 
 
3 3 4 5 
E15.5 
 
2 1 1 2 
E16.5 
 
3 2 4 Alive 2 
     
Dead 4 
E17.5 
 
5 5 6 Alive 0 
     
Dead 3 
E18.5 
 
3 5 2 Alive 0 
            Dead 6 
P21   7 4   6 0 
f/+, Srsf2f/+. f/f, Srsf2f/f. Δ/+, Srsf2Δ/+. Δ/Δ, Srsf2Δ/ Δ. E, embryonic day. P, postnatal day.681 
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Figure Legends 682 
 683 
Figure 1. SRSF2 is essential for survival of adult BM cells in vitro. (A) MSCV-IRES-EYFP 684 
empty vector (EV) or MSCV-Cre-IRES-EYFP (Cre) retrovirus-infected Srsf2 +/+ and f/f cells 685 
were seeded in duplicate, and cell number was counted with Trypan blue staining. The number 686 
of retrovirus-infected cells was determined based on EYFP expression. Cre-expressing Srsf2 687 
cKO cells (f/f Cre) showed growth suppression. (B) Apoptosis of EYFP+ cells on day 3. EYFP+ 688 
cells were gated and early apoptotic cells were defined as AnnexinV+ 7AAD- cells. Cre+Srsf2 689 
f/f cells showed significantly enhanced apoptosis. Results of three independent experiments 690 
were used for statistical calculations. * indicates p < 0.05; ** indicates p < 0.005. 691 
 692 
Figure 2. Fetal liver (FL) hematopoiesis is defective in Vav-iCre+Srsf2f/f embryos. Vav-693 
iCre+/ Srsf2f/+ mice were crossed with Srsf2f/f mice to generate Vav-iCre-Srsf2f/+ (f/+), Vav-694 
iCre+Srsf2f/+ (Δ/+), Vav-iCre-Srsf2f/f (f/f), and Vav-iCre+/Srsf2f/f (Δ/Δ) embryos. (A) 695 
Macroscopic appearance of E12.5 and E14.5 embryos. Srsf2Δ/ Δ have smaller FLs compared 696 
with the controls. (B) Relative cell numbers of E14.5 fetal livers. Each cell number was 697 
normalized to the average of f/+ FLs in the same litter. Horizontal bars show the average of 698 
each group. f/+, n = 4; f/f, n = 7; Δ/+, n = 6; Δ/Δ, n = 7. Srsf2Δ/ Δ FL cells were significantly 699 
fewer than those in other groups. (C) Apoptosis assay. Early apoptotic cells were defined as 700 
AnnexinV+ 7AAD- cells. f/+, n = 5; f/f, n = 2, Δ/+, n = 6; and Δ/Δ, n = 6. Srsf2Δ/ Δ FLs had 701 
significantly more apoptotic cells than those in other groups. (D) Cell cycle analysis by Pyronin 702 
Y and 7AAD staining. Srsf2Δ/ Δ FL cells show both a significant increase in apoptotic (sub-703 
G0/G1) cells and a decrease in cycling (S/G2/M) cells compared to other groups. f/+, n = 5; f/f, 704 
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n = 2; Δ/+, n = 6; and Δ/Δ, n = 6. (E) Histology of E14.5 FL (Hematoxylin-Eosin stain). Srsf2Δ/ Δ 705 
FL consists of hepatoblasts characterized by a large, pale-staining nucleus with distinct 706 
nucleoli (arrowhead). FLs of other genotypes are filled with hematopoietic cells, the majority of 707 
which are erythroblasts (black arrow), with scattered white blood cells (white arrow). Original 708 
magnification, ×200. Insets, ×400. Objective lens, UPlanFL N 20×/0.50, UPlanFL N 40×/0.75 709 
(both from Olympus, Tokyo). Images were acquired at room temperature using Olympus BX51 710 
microscope equipped with DP71 camera and DP controller/DP Manager software (Olympus, 711 
Tokyo, Japan). * indicates p < 0.05; ** indicates p < 0.005. 712 
 713 
Figure 3. Srsf2 null fetal livers lack hematopoietic stem/progenitor cells. (A) 714 
Representative flow cytometry results of E14.5 FL cells. Lin-neg, lineage-negative. Srsf2Δ/Δ FL 715 
lacked Lin-neg/c-Kit+ (LK) and Lin-neg/Sca1+/c-Kit+ (LSK) cells. (B) Quantification of panel A. 716 
f/+, n = 10; f/f, n = 12; Δ/+, n = 5; and Δ/Δ, n = 6. (C) Colony formation assay of E12.5 FL cells. 717 
Cells (2 × 104) were seeded in duplicate. f/+, n = 8; f/f, n = 24; Δ/+, n = 10; and Δ/Δ, n = 6. 718 
Srsf2Δ/ Δ FL cells showed significantly lower colony-forming ability than others. (D) 719 
Representative Wright-Giemsa stained cytospins of E14.5 PB. Srsf2Δ/ Δ PB lacked definitive 720 
red blood cells. (E) Quantification of panel D. f/+, n = 4; f/f, n = 5; Δ/+, n = 8; and Δ/Δ, n = 7. * 721 
indicates p < 0.05; ** indicates p < 0.005. 722 
 723 
Figure 4. Srsf2 is indispensable for survival of adult BM cells. (A) - (D) PolyIC injection 724 
into adult Mx1Cre+ or - Srsf2 cKO mice. PolyIC was injected i.p. every other day for three 725 
times into cKO mice (600 μg/dose). The day of the first injection was defined as day 0. 726 
Mx1Cre-Srsf2f/+, n = 11. Mx1Cre-Srsf2f/f, n = 23. Mx1Cre+Srsf2f/+, n = 9. Mx1Cre+Srsf2f/f, n = 727 
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24. (A) Genotyping of PB and BM cells on day16. Mx1Cre+Srsf2f/+samples showed almost 728 
complete excision of flox allele, while Mx1Cre+Srsf2f/f samples showed incomplete excision. 729 
(B) Platelet (Plt) count on day 16. (C) Total BM cells from femurs and tibias of both legs 730 
counted using Trypan blue. (D) Absolute number of LSK cells in total BM measured by flow 731 
cytometry. (E) LSK% in total BM measured by flow cytometry. (F) Competitive BMT of Mx1Cre 732 
cKO cells. One million test cells (CD45.2) were mixed with the same number of competitor 733 
cells (CD45.1) and transplanted. Chimerism in PB was evaluated by flow cytometry before 734 
(Week 0) and after polyIC injection. Five mice were in each group. Mx1Cre+Srsf2f/f cells had 735 
lower engraftment efficiency compared to others and showed continuous decrease of donor 736 
chimerism after polyIC injection. * indicates p < 0.05; ** indicates p < 0.005. 737 
  738 
Figure 5. Overexpression of WT and mutant SRSF2 has similar phenotypes. (A) Protein 739 
expression of the overexpressed SRSF2 in mouse BM cells. β-actin serves as a loading 740 
control. Signal intensities of SRSF2 and loading control were used to calculate the relative 741 
SRSF2 expression level. (B) Growth curves of total BM cells in liquid culture. Mean and SD 742 
from three independent experiments are shown. All of WT-, P95H- and Δ8aa-expressing 743 
retrovirus transduced cells showed growth disadvantage compared to MIP control cells. (C) 744 
Apoptosis assay of cells on Day 3. Combined data of independent three experiments are 745 
shown. P95H and Δ8aa cells showed enhanced apoptosis compared to MIP and WT cells. (D) 746 
Colony forming assay. Combined data of three independent experiments are shown. (E) BMT 747 
of SRSF2 overexpressing cells. Bone marrow cells were transduced with MigR1 vector, 748 
MigR1-SRSF2 WT, and MigR1-SRSF2 P95H retrovirus. Two days after initial cell infection, 749 
cells were transplanted into lethally irradiated recipient mice. Five recipients were used in each 750 
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group. Representative result of three independent experiments is shown. MigR1 recipients had 751 
higher GFP% in PB compared to SRSF2 WT and P95H counterparts. * indicates p < 0.05; ** 752 
indicates p < 0.005. 753 
 754 
Figure 6. Inducible low-level expression of mutant SRSF2 causes apoptosis and growth 755 
arrest. (A) Structure of pTRIPZ-SRSF2 constructs. Expression of microRNA-adapted shRNA 756 
against endogenous SRSF2 (shRNA-mir) and cDNA of shRNA-resistant WT or mutant human 757 
SRSF2 is driven by TRE. TRE, tetracycline inducible promoter. UBC, human ubiquitin C 758 
promoter. rtTA3, reverse tetracycline transactivator 3. IRES, internal ribosomal entry site. 759 
Puro-R, puromycin resistant gene. sinLTR, self-inactivating long terminal repeat. (B) 760 
Quantitative RT-PCR of SRSF2. The samples were measured in duplicate, and normalized to 761 
GAPDH. Expression in untreated WT cells was set to 1. 3’-UTR, endogenous SRSF2 762 
expression. Exon 2 CDS, exon 2 coding sequence representing total SRSF2 expression. (C) 763 
Growth curves. Cells were seeded in triplicate in four independent experiments and counted 764 
with Trypan blue. Dox-treated P95H and Δ8aa cells showed significant growth suppression 765 
compared to other groups. (D) Apoptosis assay. Cells were seeded in duplicate in four 766 
independent experiments. Early apoptotic cells are defined as AnnexinV+ 7AAD- cells. Dox-767 
treated P95H and Δ8aa cells showed significantly enhanced apoptosis compared to other 768 
groups. ** indicates p < 0.005. 769 
 770 
Figure 7. Target genes of WT and mutant SRSF2 by RASL-seq analysis. (A) Unsupervised 771 
hierarchical clustering show that splicing events of WT, P95H and Δ8aa (Δ8) cells in the 772 
absence of Doxycycline (Dox -) are very similar and are separated from cells with activated 773 
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shRNA/SRSF2 expression (Dox +) (Left panel). Δ8aa and P95H are grouped side by side, with 774 
Δ8aa showing stronger signal. Unsupervised hierarchical clustering of splicing events of 775 
ShSRSF2-only cells cultured in the presence or absence of Dox are also shown (right panel). 776 
Green: less short isoform, more long isoform; red: more short isoform, less long isoform. (B) Venn 777 
Diagram showing the overlap and difference of splicing events upon Dox activated expression 778 
of WT, P95H and Δ8aa SRSF2 compared to shRNA only expression. (C) Venn Diagram 779 
showing significant overlapped events (487) from P95H and Δ8aa groups relative to WT 780 
SRSF2 group. Among these shared events, over 96% are in the same direction. For these 781 
significant events changed in the same direction, Δ8aa induced changes in 450 out of 470 782 
events are over 1.5 fold compared to that in P95H induced events. (D) Validation of 10 selected 783 
RASL-seq events. Upper panel: heatmap demonstration of 10 RASL-seq events ratio (short 784 
isoform/long isoform). Green: less short isoform, more long isoform; red: more short isoform, less long 785 
isoform. Bottom panel: RT-PCR validation of 10 RASL-seq events. 786 
 787 
Figure 8. Pathway and correlation studies of target genes of WT and mutant SRSF2. (A) 788 
Top biological functions of the 470 common and same direction targets of Δ8aa and P95H 789 
based on IPA. The –log(p value) means the significance of the functions to the data set. (B) 790 
Venn Diagram showing significant overlapped events of 470 common targets of P95H and 791 
Δ8aa over WT SRSF2 relative to cells expressing only shRNA. Events changed in the same or 792 
opposite directions are also listed separately. 793 








